TORONTO–(BUSINESS WIRE)–Acerus Pharmaceuticals Corporation (TSX:ASP) will report its third
quarter financial results for the period ended September 30, 2015 on
Thursday, November 5, 2015 before the market opens.
Management of the Company will host a conference call to discuss these
results and update investors on the status of its business on Friday,
November 6, 2015 at 8:30 a.m. Eastern Time. Following the discussion,
Acerus executives will address inquiries from investment analysts.
To access the call live, please dial 416-340-2219 or 1-866-225-2055.
Listeners are encouraged to dial in 10 minutes before the call begins to
A replay of the conference call will be available until 11:59 p.m.
Eastern Time on Thursday, November 12, 2015 by dialing 905-694-9451 or
1-800-408-3053, using access code: 2619492#.
Acerus Pharmaceuticals Corporation is a Canadian pharmaceutical company
focused on the development, manufacture, marketing and distribution of
innovative, branded products that improve the patient experience.
Acerus markets ESTRACE® in Canada, a product indicated for
the symptomatic relief of menopausal symptoms. NATESTO™, a product
utilizing an Acerus licensed nasal gel technology, is the first and only
testosterone nasal gel approved and launched in the United States for
replacement therapy in adult males diagnosed with hypogonadism, and is
currently filed for approval in Canada. The commercial rights to
NATESTO™ in the United States and Mexico have been licensed by Acerus to
an affiliate of Endo International plc. TEFINA™, a ‘use as required’
nasal testosterone gel, is an Acerus drug development candidate aimed at
addressing a significant unmet need for women with female orgasmic
Acerus Pharmaceuticals Corporation
Tiana DiMichele, 416-679-0822
Marketing & Communications